Management of hepatitis B after renal transplantation: An update

Journal of Nephrology

Volumn 15, Issue 2, 2002, Pages 113-122

  Fabrizi, Fabrizio ^a   Lunghi, Giovanna ^a   Poordad, Fred F ^a   Martin, Paul ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Hepatitis B; Lamivudine; Renal transplantation

Indexed keywords

ACICLOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; FAMCICLOVIR; FIALURIDINE; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; PREDNISOLONE; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; STEROID; TACROLIMUS; UNINDEXED DRUG; VIDARABINE; VIRUS DNA; ZIDOVUDINE;

BIOCHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; GASTROINTESTINAL DISEASE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER DISEASE; NONHUMAN; PARESTHESIA; RECIPIENT; REVIEW; SERODIAGNOSIS; SIDE EFFECT; TREATMENT OUTCOME; VIROLOGY; VIRUS INHIBITION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; GENETICS; MUTATION; RECURRENT DISEASE;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMAN; INTERFERON-ALPHA; KIDNEY TRANSPLANTATION; LAMIVUDINE; MUTATION; RECURRENCE; HUMANS;

EID: 0035988261     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Hepatitis in kidney transplantation
2. Chronic viral hepatitis and the management of chronic renal failure
3. Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: Yellow spots on a blank map?
4. Hepatitis virus infection in haemodialysis patients from Moldavia
5. Serological and vaccination profile of hemodialysis patients during an outbreak of hepatitis B virus infection
6. Hepatitis B virus: Genotypes and subtypes in Brazilian hemodialysis patients
7. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy
8. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Reports of a prospective study
9. Liver transplantation for viral hepatitis: Current status
10. Impact of hepatitis B and C virus on kidney transplantation outcome
11. Renal transplant recipients and chronic liver disease: Statistical evaluation of predisposing factors
12. Prevalence and clinical course of hepatitis B and hepatitis C liver disease in cyclosporin-treated renal allograft recipients
13. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection
14. Co-infection by hepatitis B virus and hepatitis C virus in renal transplantation: Morbidity and mortality in 1098 patients
15. Impact of HBs antigenemia on long-term patient survival and causes of death after renal transplantation
16. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease
17. The treatment of chronic viral hepatitis
18. The epidemiology of viral hepatitis in the United States
19. Hepatitis B virus infection
20. A longitudinal follow-up of asymptomatic hepatitis B surface antigen positive Chinese children
21. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B
22. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
23. A long-term follow-up study of asymptomatic hepatitis B surface antigen positive carriers in Montreal
24. Chronic persistent hepatitis type B can be a progressive disease when associated with sustained replication
25. Detection of hepatitis B virus DNA in serum by a simple spot hybridization technique: Comparison with results for other viral markers
26. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
27. Management of hepatitis B: 2000-Summary of a Workshop
28. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection
29. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B
30. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B
31. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection
32. Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature
33. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy
34. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
35. Long-term remission of chronic hepatitis B after alpha-interferon therapy
36. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy
37. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa
38. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
39. Mechanisms of action of interferons
40. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: Mechanism of action
41. The effects of interpheron alpha on the production and actions of other cytokines
42. Mechanism of interferon action: Functional characterization of positive and negative regulatory domains that modulate transcriptional activation of the human RNA-dependent protein kinase Pkr promoter
43. Chronic hepatitis B virus infection: Treatment strategies for the next millennium
44. Hepatitis B infection: Pathogenesis and management
45. New nucleoside analogues for chronic hepatitis B
46. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine
47. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction
48. A one-year trial of lamivudine for chronic hepatitis B
49. A preliminary trial of lamivudine for chronic hepatitis B infection
50. Lamivudine as initial treatment for chronic hepatitis B in the United States
51. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
52. Imminent liver failure in a hepatitis-B-positive renal-allograft recipient: Successful therapy with interferon-α
53. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients
54. Adverse effects of low dose prophylactic human recombinant leucocyte interferon-alpha treatment in renal transplant recipients
55. Recombinant interferon in renal allograft recipients with chronic hepatitis C
56. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C
57. Interferon-α-induced acute renal allograft rejection
58. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation
59. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients
60. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients
61. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients
62. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients
63. Results on preemptive or prophylactic treatment of lamivudine in HBsAg(+) renal allograft recipients: Comparison with salvage treatment after hepatic dysfunction with HBV recurrence
64. Chronic hepatitis B treatment with lamivudine in kidney transplant patients
65. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
66. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease
67. Type, prevalence and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease
68. Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine
69. Selection of mutations in the hepatitis B virus polymerase during therapy of transplanted recipients with lamivudine
70. Mutation in the HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
71. Hepatitis B virus resistance to lamivudine for recurrent infection after orthotopic liver transplantation
72. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
73. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
74. Antiviral chemotherapy for the treatment of hepatitis B virus infections
75. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
76. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient
77. Lamivudine for treating active hepatitis B in renal transplant recipients: A case report
78. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
79. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials. International Lamivudine Investigator Group
80. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea
81. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers
82. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
83. Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease. Part I: Analysis of 1744 HBsAg carriers
84. Hepatitis B genotypes and the response to interferon therapy
85. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw